.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 5,490,991

« Back to Dashboard

Details for Patent: 5,490,991

Title: Directed delivery of radioprotectants using a receptor specific carrier
Abstract:Chemoactive radioprotectants are coupled to carrier molecules capable of binding cell receptors to form complexes that can be directed to specific non-target cells in a mixture of cells prior to radiation of the mixture so that target cells are selectively destroyed while the non-target cells are protected from radiation. Radioprotection of non-target cells is provided by using chemoactive radioprotectant complexes.
Inventor(s): Enriquez; Philip (Sheldonville, MA), Jung; Chu W. (Arlington, MA), Groman; Ernest V. (Brookline, MA)
Assignee: Advanced Magnetics, Inc. (Cambridge, MA)
Filing Date:Apr 05, 1993
Application Number:08/043,611
Claims:1. A method of treating a mixture of cells containing target cells to be destroyed by radiation therapy and non-target cells so as to protect specific non-target cells in the mixture against damage, comprising:

(i) selecting a radioprotectant compound;

(ii) forming a complex of the radioprotectant compound and a carrier wherein the carrier is both (i) a polysaccharide, and (ii) capable of being bound to a receptor mediated endocytosis (RME) receptor, the RME receptor being present on the non-target cells and substantially absent on the target cells; and

(iii) administering the complex to the mixture of cells.

2. A method according to claim 1, wherein the radioprotectant is a chemoactive radioprotectant compound.

3. A method according to claim 1, wherein the non-target cells of step (iii) are bone marrow cells.

4. A method according to claim 1, wherein the non-target cells of step (iii) are liver cells.

5. A method according to claim 2, wherein the radioprotectant agents are selected from the group consisting of antioxidants, enzymes, and free radical scavengers.

6. A method according to claim 1, wherein the carrier of step (ii) is selected from the group consisting of arabinogalactan, mannan, and fucoidan.

7. A method according to claim 5, wherein the carrier of step (ii) is selected from the group consisting of arabinogalactan, mannan, and fucoidan.

8. A method according to claim 5, wherein the antioxidants are sulfhydryl compounds.

9. A method according to claim 1, wherein the complex of the radioprotectant and polysaccharide carrier is capable of binding to an asialoglycoprotein receptor.

10. A method according to claim 1, wherein the complex of the radioprotectant and polysaccharide carrier is capable of binding to a mannose receptor.

11. A method according to claim 1, wherein the complex of step (ii) is a micelle comprising the polysaccharide associated with the radioprotecting compound.

12. A method of treating animal subjects having diffuse cancerous infiltrations with radiation comprising:

(i) selecting a polysaccharide carrier capable of interacting with an RME cell receptor;

(ii) modifying the carrier to form a complex with a radioprotectant agent;

(iii) administering to the subject an effective dose of the complex prior to radiation treatment so as to protect non-target cells during subsequent radiation of tissues at doses sufficient to destroy malignant cells.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc